Study on the blood-borne virus co-infection and T lymphocyte subset among intravenous drug users

Table 5 CD percentages and cytokine level in IDU with HIV and HCV co-infection (mean ± SD)

Group	n	CD3 (%)	CD4 (%)	CD8 (%)	CD4/CD8	IFN-γ(ng/L)	IL-4 (ng/L)
Negative1	40	56.80 ± 4.42	41.9 ± 4.16	29.08 ± 2.85	1.44 ± 0.13	288.01 ± 40.03	20.76 ± 1.87
HCV infection	45	58.23 ± 4.70	41.42 ± 3.65	29.33 ± 2.52	1.41 ± 0.12	282.86 ± 54.77	20.88 ± 1.42
HIV infection	27	54.27 ± 4.23b	39.49 ± 3.47a	28.98 ± 3.11	1.36 ± 0.15b	265.43 ± 38.71a	20.23 ± 1.34
HIV+HCV-RNA-	40	54.02 ± 3.66b	39.29 ± 2.91b	28.81 ± 2.42	1.36 ± 0.13b	261.59 ± 43.68a	20.46 ± 1.38
HIV+HCV-RNA+	25	53.82 ± 3.15b	39.51 ± 2.91*	28.58 ± 2.53	1.38 ± 0.13b	263.57 ± 43.65a	20.84 ± 1.56

^aP < 0.05,

^bP < 0.01 vs negative cases.

¹Viral infection markers were not discovered in IDU.